Axsome Therapeutics (AXSM) Soars 5.77% on Positive Analyst Ratings

Axsome Therapeutics (AXSM) shares surged 5.77% intraday, marking a five-day winning streak and reaching their highest level since May 2025, with a cumulative gain of 9.11% over the past five days.

Recent analyst ratings have been favorable for Axsome Therapeutics. Wells Fargo maintained a "Buy" rating with a price target of $165.00, while HC Wainwright reissued a "buy" rating with a higher price target of $180.00. These ratings reflect a positive outlook on the company's prospects and have likely contributed to the recent upward trend in the stock price.

Investors are also anticipating the release of Axsome Therapeutics' Q2 2025 financial results, scheduled for August 4, 2025. This report will provide crucial insights into the company's financial performance and strategic initiatives, potentially influencing investor sentiment and stock price movements.

Axsome Therapeutics' focus on central nervous system (CNS) disorders, with FDA-approved treatments and multiple late-stage development programs, positions the company for potential growth. Any updates on clinical trials or regulatory progress could further impact the stock's performance, as these developments are closely watched by investors and analysts alike.